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Tumour necrosis factor-alpha (TNF) has been used in the clinic
for more than 10 years in an isolated limb perfusion (ILP). How-
ever, intra-tumoural expression of TNF receptor-1 (TNF-R1) and
TNF-R1 upregulating factors are unknown. We determined the
expression of TNF-R1, proEMAP and endothelial monocyte-acti-
vating polypeptide-II (EMAP-II) before and after ILP and eval-
uated this against clinical response. Tumour biopsies were taken
before and after ILP of patients (n 5 27) with advanced sarcoma
or metastatic melanoma. Biopsies were randomly analysed by
western blotting for proEMAP/EMAP-II and TNF-R1 expression.
Appropriate melanoma biopsies were stained for EMAP-II, TNF-
R1, CD31 and CD68. For melanomas we found that an up-regula-
tion of EMAP-II, in contrast to proEMAP or TNF-R1, directly af-
ter ILP significantly correlated with a complete tumour response.
No correlation was found for sarcoma patients. In a comparative
analysis we found that the overall proEMAP and EMAP-II
expression was higher in melanoma as compared to sarcoma cases
and measurements in cell lines revealed high proEMAP expres-
sion by melanoma cells. We report high EMAP-II expression by
endothelial cells and association with macrophages. In addition,
macrophages are recruited to vessel-remnants after ILP. An upre-
gulation of EMAP-II directly after ILP of melanoma patients cor-
relates with and might predict a complete response to TNF-based
ILP. The association of macrophages with EMAP-II expression
and vascular damage suggests a role for EMAP-II in regulating
the TNF-based anti-tumour effects observed with an ILP. Analysis
of EMAP-II expression in melanoma biopsies should be imple-
mented in the ILP procedure.
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In the clinic, TNF is currently used in an isolated limb perfusion
(ILP) setting and is registered in Europe since 1998.1 Patients with
soft tissue sarcoma (STS) or in transit melanoma metastases in the
extremities treated by an ILP with TNF and melphalan respond
very well and 75% limb salvage is achieved with up to 80%
response rates in patients with limb threatening locally advanced
STS2,3 whilst a 70% or higher complete response (CR) rate is
achieved in patients with melanoma in transit metastases.4,5 Re-
sponding tumours show hemorrhagic necrosis and the TNF effect
seems tumour associated vasculature-dependent.1 Molecular data
on intra-tumoural expression of TNF-R1 and TNF-R1 upregulat-
ing factors however do not exist.
Endothelial monocyte-activating polypeptide-II (EMAP-II) is a
multifunctional cytokine that was first isolated from supernatants
of cultured murine fibrosarcoma and human melanoma cells.6,7
Even before it was named, its enhancing effects on tumour necrosis
factor-alpha (TNF)-induced hemorrhagic tumour response were
reported.8 EMAP-II induces chemo taxis of neutrophils and mono-
cytes/macrophages and an induction of von Willebrand Factor,
E- and P-selectin and Tissue Factor in endothelial cells.9,10 In
addition, EMAP-II exhibits antiangiogenic activities by inducing
endothelial cell apoptosis and suppression of tumour growth.11
Recently, a cancer cell dependent novel immunosuppressive role of
EMAP-II by inducing lymphocyte apoptosis has been described.12
EMAP-II is transcribed in all cells as proEMAP and involved in
protein translation as component of the tRNA synthase complex.13
For TNF-resistant tumours EMAP-II is shown to sensitise those
tumours towards TNF upon EMAP-II gene transfer. These sensi-
tising properties were not seen on tumour cells in vitro, suggesting
an anti-tumour effect at vascular level. This was confirmed by a
strong increase in Tissue Factor induction by high EMAP-II
expressing tumours compared to wild type.14,15 Another relation
between TNF and EMAP-II was found in endothelial cells in
which EMAP-II was capable of inducing an up-regulation of
TNF-R1 mRNA expression.16 However, this up-regulation on
mRNA level did not correspond to protein levels and in a recent
gene array study no records on EMAP-II-altered TNF-R1 expres-
sion were found17 suggesting that the relation between EMAP-II
and TNF-R1 is more complex. In a rat model we showed that high
EMAP-expressing tumours show a better response to TNF in an
ILP.18 This TNF-sensitising effect of EMAP-II initiated studies on
the role of EMAP-II in the clinical application of TNF in cancer
treatment.
In the current study we show data on TNF-R1 and EMAP-II pro-
tein expression in tumours from patients treated with a TNF-mel-
phalan ILP. In a double blind set-up we evaluated and quantified
proEMAP, EMAP-II and TNF-R1 protein expression both before
and after ILP of sarcoma and melanoma patients (total n 5 27). In
addition, comparative analysis, histology and immunofluorescence
stainings of melanoma to locate these proteins were done. The
TNF-R1 and EMAP-II distribution within tumour tissue before and
after ILP treatment indicates possible underlying mechanisms of
the observed anti tumour effects of an ILP treatment.
Material and methods
Patients
At the Erasmus MC-Daniel den Hoed Cancer Centre more than
350 TNF-based ILPs were performed between 1991 and 2002 in
soft tissue sarcoma and melanoma bearing patients. Because of
the multifocality of the tumours and impossibility of surgical
resection, all patients were potential candidates for amputation.
Tumour material from these patients was stored in a tumour bank.
Corresponding tumour biopsies before and after ILP were avail-
able for 11 patients. Only 2 melanoma patients received a mel-
phalan alone ILP and no appropriate biopsies were available from
these patients. Patients were included when a standardized taken
biopsy was available both pre- and post-ILP. To expand this group,
extra biopsies were taken from patients treated between 2001 and
2004. In total, 27 patients (14 suffering from sarcoma and 13 suffer-
ing from melanoma) were included in our study. Because of the
nature of the biopsies, sarcomas were used for western blotting
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experiments and appropriate melanomas were used for immuno-
fluorescence as well. TNF-based ILP with TNF and melphalan is a
registered treatment modality for patients with limb threatening
tumours, the protocols are approved by the Medical Ethical Com-
mittee of the Erasmus University Medical Centre and an informed
consent form was obtained from all patients. Patients and tumour
characteristics are listed in Table I.
Isolated limb perfusion
TNF-based ILP procedure has been described previously.2,3
Besides lymph node dissection, (for melanoma patients under-
going an iliac perfusion or with palpable lymph nodes) a tumour
biopsy was taken directly before and directly after (within 1–
2 minutes) the ILP procedure. The biopsies were directly frozen
and stored at 280C until analysis. Response rates were reported
according to WHO criteria19 in which a complete response (CR) is
disappearance of all lesions with no new areas of disease appear-
ing in the ILP regions. Partial response (PR) is defined as a reduc-
tion of 50–99% of the total tumour size and a stable disease (SD)
is defined as no change after ILP treatment. The final outcome of
the ILP consists of the clinical and histological response.
Tissue lysis and Western blotting
Tumour lysates were prepared in freshly made Lysis Buffer
(50 mM Pipes/KOH, pH 6.5, 2 mM EDTA, 0.1% Chaps, 5 mM
DTT, protease inhibitor cocktail (Roche Diagnostics)), 100 ll per
25 mg tumour-tissue and the samples were subjected to 3 freeze-
thaw cycles. Cultured tumour cells were lysed as described later.
Samples were centrifuged for 10 min at 14,000 rpm at 4C and
within the clear supernatant the protein concentration was deter-
mined using Coomassie Reagent (Uptima). One hundred micro-
grams of tumour lysate or 150 lg of total protein from cultured
cells was resolved by SDS-PAGE, transferred to polyvinylidene
difluoride membranes (BioRad) and analysed by Western blotting
using rabbit anti-human EMAP-II (BioSource) or mouse anti-
human TNF-R1 (R&D Systems). Expression was quantified by
densitometric analysis using ImageJ Software (NIH) and com-
pared to positive control (recombinant protein) for EMAP-II (Bio-
Source) or expressed as absolute total density (averaged pixel
value times the number of pixels) for TNF-R1.
Cell culture
B16BL6 (mouse melanoma), BLM (human melanoma) and
Mel57 (human melanoma) cells were cultured in DMEM medium
(Biowhittaker), BN175 (rat syngeneic soft tissue sarcoma) cells
were cultured in RPMI 1640 medium (Biowhittaker), ROS-1 (rat
osteo sarcoma) cells were cultured in EMEM medium supple-
mented with 10% Fetal Calf Serum (FCS) and 100 U/ml penicil-
lin/streptomycin (Life Technologies). Tumour cells were main-
tained at 37C, 5% CO2 in a humidified incubator and routinely
subcultured by removal from flasks using Trypsin-EDTA (Sigma-
Aldrich). Human umbilical vein endothelial cells (HUVEC) were
used between passage 3 and 7 and maintained in Human endothe-
lial-SFM medium supplemented with 10% new-born calf serum,
5% Human Serum (Invitrogen), 20 ng/ml bFGF and 100 ng/ml
EGF (PeproTech), in gelatin-coated flasks.
ELISA
Total EMAP concentrations were determined in tumour cell
lysates. Tumour cells were counted and lysed in 75 ll/1.106 cells
Lysis Buffer (50 mM Tris-HCl (pH 7,4), 150 mM NaCl, 1 mM
EDTA, 1% NP-40, protein inhibitor cocktail) for 30 min on ice.
Cell lysates were cleared from cellular debris by centrifugation for
10 min at 0C, 14,000 rpm and stored at 280C until analysis.
ELISA was performed using the Accucyte Human EMAP-2 Kit
for detection of total EMAP-2 (CytImmune) using the provided
reagents according to the manufacturers instructions.
Immunofluorescence stainings
Cryosections (5 lm) of Tissue-Tek (Sakura) embedded mela-
noma biopsies were fixed on polylysine-coated slides with ace-
tone, air-dried and rehydrated with PBS. Tissue sections were
TABLE I – PATIENT AND TUMOUR CHARACTERISTICS. THE 14 SARCOMA AND 13 MELANOMA PATIENTS CONSIST OF 15 FEMALES (56%)
AND 12 MALES (44%), THE AVERAGE AGE IS 63 (RANGE 20–88)
Pat. no. Sex Age (y) Tumor type Subtype sarcoma Number of tumors Site Grade Stage ILP type Response to ILP
1 F 65 S Pleiomorphic >10 Lower leg High PT Fem SD
2 M 74 S Kaposi >10 Lower leg/foot Low PT Fem CR
3 M 74 S Pleiomorphic 1 Upper arm High PT Axil SD
4 M 41 S Lipo 4 Upper/lower
leg, knee
High LR Iliac PR
5 M 73 S Leiomyo >10 Upper arm High LR Axil PR
6 M 54 S Pleiomorphic 1 Upper leg High PT Iliac PR
7 F 68 S Leiomyo 1 Lower leg High PT Fem PR
8 M 88 S Angio 6 Ankle/foot Med LR Fem CR
9 M 50 S Neuro 1 Upper leg Med Met Iliac PR
10 M 20 S Aggressive fibro 8 Upper/lower leg Low LR Iliac PR
11 F 73 S Clear 1 Upper leg High Met Iliac PR
12 F 82 S Mal fibr histiocyt 1 Upper leg High PT Iliac PR
13 M 51 S Pleiomorphic 1 Upper arm High LR Axil PR
14 F 45 S Stuart-Treves >100 Upper leg Med PT Iliac PR
15 F 82 M – >50 Lower leg – Met, PLN Iliac PR
16 F 77 M – >100 Total leg – Met. PLN Iliac –1
17 M 78 M – >100 Lower leg, foot – PT, Dmet Iliac PR
18 F 62 M – <10 Lower arm – Met, PLN Axil CR
19 M 25 M – >100 Lower leg, foot – PT, Dmet Iliac PR
20 F 57 M – >50 Total leg – Met, PLN Iliac CR
21 M 64 M – >20 Lower leg – Met, PLN Fem CR
22 F 83 M – >50 Lower leg – Met, PLN Fem CR
23 F 66 M – <10 Lower leg, foot – Met Fem CR
24 F 65 M – >100 Total leg – Met, PLN Iliac SD
25 F 77 M – <10 Lower leg, foot – Met, PLN Iliac PR
26 F 76 M – >50 Total leg – Met Iliac CR
27 F 46 M – >20 Total leg – Met, PLN Iliac SD
1Patient no. 16 died 4 days after ILP due to a myocardial infarction. This patient was included for expression studies but excluded from statis-
tical analysis. Abbreviations: F, female; M, male; S, sarcoma; M, melanoma; Med, medium; PT, primary tumour; LR, local recurrence; Met, me-
tastases; PLN, positive lymph nodes; Dmet, distal metastases; Fem, femoral ILP; Axil, axilar ILP; Iliac, Iliac ILP; SD, stable disease, CR, com-
plete response; PR, partial response.
1482 VAN HORSSEN ET AL.
incubated in blocking solution (1% BSA/0.05% Tween-20/PBS)
for at least 30 min and subsequently incubated with primary anti-
bodies (rabbit anti-human TNF-R1, R&D Systems, mouse anti-
human TNF-R1, Alexis, rabbit anti-human EMAP-II, BioSource,
sheep anti-human CD31, R&D Systems, mouse anti-human
CD68, DaKo Cytomation) for 1 hr at room temperature (CD31,
CD68) or overnight at 4C (EMAP-II, TNF-R1) followed by green
(488) and red (594) labelled Alexa Fluor secondary antibodies
(Molecular Probes) for 1 hr at room temperature. Specificity of the
antibodies used was checked by staining with secondary antibod-
ies alone. Slides were mounted using a 1:1 solution of VectaShield
(Vector Laboratories) and DAPI–DABCO (Molecular Probes).
Immunofluorescent images were taken using an Axiovert 100 M
microscope with 403/1.30 Oil-Plan-NEOFLUAR objective lens
(Carl Zeiss) and an ORCA II ER camera (C4742-98, Hamamatsu
Photonics Systems) with Openlab 3.1.5 software (Improvision).
HE staining
The same tumour biopsies of melanoma patients used for west-
ern blot analysis were used for histological analysis. Five-micro-
metre cryosections of Tissue-Tek (Sakura) embedded melanoma
biopsies were fixed on polylysine-coated slides with acetone, air-
dried and rehydrated with PBS. Sections were stained with haema-
toxylin and eosin using standard procedures. Slides were exam-
ined on a Leica DM-RXA microscope and photographed using a
Sony 3CCD DXC 950 camera.
Statistical analysis
ProEMAP, EMAP-II and TNF-R1 expression were divided in
up- and down regulated after ILP treatment. Expression threshold
was set at >5% compared to control and an upregulation was con-
sidered relevant when it was at least 1.2 times higher compared to
before treatment. ProEMAP and EMAP-II were compared to
TNF-R1 expression and clinical outcome using cross tabulation
and Chi-Square tests. All tests were 2 sided and the cutoff level
for statistical significance was set at p < 0.05.
Results
Patients
Twenty-seven patients were included in our study, divided in 14
suffering from sarcoma and 13 suffering from melanoma confined
to leg or arm. All patients were treated with an ILP with a combi-
nation of TNF and melphalan. Patients were included when a
standardized taken tumour biopsy was available from just before
and immediately after ILP. From 1 patient (no. 21) also normal
skin biopsies were taken. From 1 patient (no. 16) no response data
were available because this patient died 4 days after a leakage-free
ILP due to a myocardial infarction and was known with a previous
cardiac history. Patient characteristics are summarized in Table I.
EMAP-II and TNF-R1 expression before and after
ILP in sarcoma patients
Figure 1a shows protein expression of EMAP-II and TNF-R1 in
14 sarcoma patients before (b) and after (a) ILP. All sarcoma
patients show proEMAP expression although in patient 3 and 14
the expression is very low. The mature cytokine EMAP-II was
also observed in nearly all sarcoma biopsies although it was very
low in a number of patients. In addition some intermediate forms
were observed which is in accordance with previous reports.20,21
Also TNF-R1 expression was found in almost all sarcoma
patients. For proEMAP, EMAP-II and TNF-R1 protein expression
varied a lot between patients and before and after ILP. ProEMAP
and EMAP-II expression were quantified using densitometric
analysis and illustrated as percentage of control (recombinant
FIGURE 1 – Western blot analysis of EMAP-II and TNF-R1 expression in tumour biopsies from sarcoma patients taken right before (b) and af-
ter (a) TNF-based ILP. (a) Western blots. 1C, 50 ng recombinant EMAP-II protein, for TNF-R1 no positive control was available. (b) Quantifi-
cation of proEMAP expression before (open bars) and after (closed bars) ILP as compared to the positive control. (c) Quantification of EMAP-II
expression before and after ILP as compared to the positive control. (d) Ratio of EMAP-II/proEMAP derived from (b) and (c) before and after
ILP. (e) Quantification of TNF-R1 expression before and after ILP shown as absolute density values.
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EMAP-II) before and after ILP (Figs. 1b and 1c). Because activ-
ities are attributed to the active form, as a derivative of these quanti-
tative data the ratio EMAP-II/proEMAP was calculated (Fig. 1d).
The quantification of TNF-R1 expression is illustrated as total abso-
lute density because no positive control was available (Fig. 1e).
EMAP-II and TNF-R1 expression before and after
ILP in melanoma patients
For 13 melanoma patients (patient 15–27) the same analyses
were performed as for the sarcoma patients. Except for patient 24,
all melanoma patients show proEMAP expression and EMAP-II
was found in all biopsies (Fig. 2a). Similar to the sarcoma patients
some intermediate forms were observed as well. TNF-R1 expres-
sion was found in all melanoma patients although very low in
patient 24 and 27. Quantitative analysis of proEMAP and EMAP-
II expression was done and expressed as percentage of control
(Figs. 2b and 2c). The derived ratio EMAP-II/proEMAP is shown
in Figure 2d and the absolute total density values for TNF-R1
expression in the melanoma patients are depicted in Figure 2e.
When comparing Figures 1a and 2a, the expression of proEMAP
and EMAP-II in melanoma biopsies was more abundant than in
sarcoma biopsies.
Correlation analysis
To demonstrate statistical correlation between proEMAP,
EMAP-II and TNF-R1 expression and response rates we per-
formed Chi-Square analysis. We divided the patients in up- and
down-regulation of proEMAP, EMAP-II and TNF-R1 protein
expression upon ILP treatment. An upregulation of 1.2-fold and
expression of >5% were set as thresholds. A 1.2 increase was con-
sidered relevant in terms of measurements used and to prevent
inclusion of observed upregulations that are too small to be bio-
logically relevant. Whether this 1.2 increase is biologically rele-
vant in itself cannot be concluded but local upregulation is known
to be of crucial importance for EMAP-II to exert its biological
activities (see discussion section). In addition, the patients were
divided in complete responders (CR) at 1 site and partial respond-
ers (PR) or stable disease (SD) at the other. The successes (up-reg-
ulation and CR) were correlated to the failures (down regulation
and PR/SD) for sarcoma and melanoma patients by cross tabula-
tion and Chi-Square analysis. The p-values for significance are
shown in Table II. An up-regulation of proEMAP or the ratio did
not correlate with an up-regulation of TNF-R1 or a CR for mela-
noma patients. In contrast, a significant correlation was found
between an up-regulation of EMAP-II and a CR for melanomas
(p 5 0.018). Thus, when EMAP-II is upregulated directly after
ILP treatment, the patient is expected to have a CR. Up-regulation
of EMAP-II therefore could be an independent prognostic marker
for a CR of melanoma patients. Between an up-regulation of TNF-
R1 and CR no relation was found (Table II). For sarcoma patients
no positive correlation was found.
TABLE II – CORRELATION STATISTICS SHOWING p-VALUES OF
CHI-SQUARE ANALYSIS. ALL TESTS WERE TWO SIDED AND THE CUT-OFF
LEVEL FOR STATISTICAL SIGNIFICANCE WAS SET AT p < 0.05. ARROW





Ratio (act/pro) 0.699 0.260
TNF-R1› – 1.000
FIGURE 2 – Western blot analysis of EMAP-II and TNF-R1 expression in tumour biopsies from melanoma patients taken right before (b) and
after (a) TNF-based ILP. (a) Western blots. 1C, 50 ng recombinant EMAP-II protein, for TNF-R1 no positive control was available. (b) Quanti-
fication of proEMAP expression before (open bars) and after (closed bars) ILP as compared to the positive control. (c) Quantification of EMAP-
II expression before and after ILP as compared to the positive control. (d) Ratio of EMAP-II/proEMAP derived from (b) and (c) before and after
ILP. (e) Quantification of TNF-R1 expression before and after ILP shown as absolute density values.
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Comparative analysis of proEMAP/EMAP-II expression
in sarcoma and melanoma
An upregulation of EMAP-II did correlate with CR in mela-
noma patients but not in sarcoma patients. Comparing these
2 groups for relative proEMAP and EMAP-II expression revealed
that for both proEMAP and EMAP-II, both before and after ILP,
melanoma tumour biopsies had a higher relative expression
(Fig. 3a). The differences were most profound for EMAP-II (in
melanoma 1.8 times higher before and after ILP), proEMAP was
1.6 and 1.3 times higher in melanoma before and after ILP respec-
tively. For a more detailed analysis we also compared subgroups
within sarcoma and melanoma patients. Sarcoma cases were di-
vided according to grade and stage (Fig. 3b). Although some sub-
groups were very small, some interesting differences were
observed. Both before and after, ILP proEMAP was the highest in
medium-grade sarcomas while for EMAP-II this only was the case
after ILP. The abundant upregulation of EMAP-II after ILP in the
medium-grade sarcomas (from 8.2 to 25%) resulted from 3
patients (no. 8, 9 and 14) with 1 CR and 2 PR. The 2 SD patients
(no. 1 and 3) were both high-grade sarcomas and for this group a
downregulation for EMAP-II after ILP was found. When compar-
ing the different stages before ILP proEMAP was the highest in
the local recurrence (LR) patients, while after ILP patients with
metastases (Met) had highest proEMAP expression (Fig. 3b, lower
panel). However, EMAP-II expression in the Met-subgroup was
almost absent while the 2 patients (no. 9 and 11) did have a PR.
For Primary Tumours (PT) we observe the most abundant upregu-
lation of EMAP-II after ILP (from 7.5 to 14.9%) but although
most of the PT sarcoma patients had a PR also 2 patients of this
group had a SD.
Melanoma patients were divided according to stage (Fig. 3c).
For all subgroups, except for the Met group after ILP, the pro-
EMAP expression was very high. Interestingly, for EMAP-II the
opposite was the case: EMAP-II expression was very high after
ILP in the Met patient group (40.4%). Patients (no. 23 and 26)
within this group did have a CR although also before ILP the
EMAP-II expression was already high in these 2 patients. In con-
clusion, we observed higher proEMAP/EMAP-II levels in mela-
noma patients and although these groups were too small to draw
any conclusions, some interesting differences were found between
the subgroups.
ProEMAP/EMAP-II expression in tumour cell lines
For a further analysis of cellular proEMAP/EMAP-II expression
by melanoma and sarcoma cells we evaluated the expression in
some melanoma and sarcoma cell lines available in the lab. Using
quantitative western blotting the 2 human melanoma cell lines
analysed (BLM, Mel57) had the most abundant proEMAP expres-
sion although the differences with ROS-1 and HUVEC were small
(Figs. 3d and 3e). The relatively high proEMAP levels in the en-
dothelial cell line did correspond with the co-staining experiments
(see later). Surprisingly, we observed differences between species
of EMAP-II active forms. For the human cells (BLM, Mel57 and
HUVEC) the apparent molecular weight was 18–19 kD while for
the mouse and rat lines (B16, BN175 and ROS-1) it was around
16–17 kD. For all cell lines the EMAP-II expression was very low
(Fig. 3e, right graph). In addition, ELISA was performed for total
EMAP within lysates of tumour cells. For Mel57 and BLM mela-
noma lines EMAP concentration was higher as compared to the
FIGURE 3 – Comparative analysis of proEMAP/EMAP-II expression in melanoma and sarcoma tumours. (a) Table showing overall relative
proEMAP/EMAP-II expression in the sarcoma and melanoma biopsies before and after ILP. In melanoma all relative values are higher as com-
pared to sarcoma. (b) ProEMAP/EMAP-II expression in sarcoma patients subdivided by grade or stage of the tumour. For abbreviations see
legend Table I. (c) ProEMAP/EMAP-II expression in melanoma patients subdivided by stage of the tumour. Note the high EMAP-II expression
in 2 patients with metastases after ILP. For abbreviations see legend Table I. (d) Western blot analysis of EMAP expression in tumour cell lines.
Three melanomas (B16, BLM, Mel57) were compared with 2 sarcoma lines (BN175, ROS1). HUVEC were used as EC control. (e) Quantifica-
tion of western blot analysis showing the relative proEMAP/EMAP expression as compared to positive control. Note the very low EMAP-II
expression of the cultured (unstimulated) cells. (f) Total EMAP concentration in tumour cell lysates measured by ELISA.
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other cell lines. The values for the sarcoma lines BN-175 and
ROS-1 were lower and very low respectively as determined by the
ELISA procedure (Fig. 3f).
Immunofluorescent detection of EMAP-II and TNF-R1
in melanoma biopsies
Double fluorescent staining for EMAP-II and TNF-R1 expres-
sion before and after ILP treatment are shown in Figure 4a. Before
ILP it is obvious that all cells express proEMAP-EMAP-II due to
the function of proEMAP in protein translation. In some vessel-
like regions throughout the biopsy a higher expression was found
(arrow). Before ILP, TNF-R1 expression was found in a fraction
of the cells while these high TNF-R1 expressing cells located
nearby the vessel-like structures. Evidently, the high expressing
EMAP-II cells and the high expressing TNF-R1 cells do not over-
lap as shown in the merged image (Fig. 4a, upper panel). After
ILP the tumour structure is completely disrupted and no vessel-
like structures were observed anymore. EMAP-II expression was
still seen in all cells and some clustering of high EMAP-II
expressing cells was noted (Fig. 4a, lower panel). TNF-R1 expres-
sion after ILP was found in a fraction of the cells and its expres-
sion seemed reorganized as receptor-clusters (arrowheads). The
high expressing EMAP-II cells after ILP did not correlate with the
high expressing TNF-R1 cells. To compare these immunofluores-
cence data with tumour histology HE stainings were done of the
same biopsies (Fig. 4b). Before-ILP (upper panel) heterogeneous
tumour histology is observed with characteristics of malignant
melanoma like differences in tumour nuclei dimensions, tumour
infiltrate and tumour-associated vessels (asterisk). The right panel
shows an example of melanoma vessel(s) before ILP. After ILP
(lower panel) the tumour histology is reorganised, cells that have a
macrophage appearance tend to cluster (asterisk). The vessel in
the right panel shows also association with infiltrate-like cells.
Localization of EMAP-II and TNF-R1 in melanoma biopsies
before and after ILP
To localize EMAP-II and TNF-R1 expression in the heteroge-
neous tumour sections we co-stained EMAP-II and TNF-R1 to-
gether with endothelial (CD31) and macrophages/monocytes
marker (CD68) before and after ILP (Fig. 5). As shown in Figure
5a, the vessel-like structures found with the EMAP-II staining in
Figure 4 indeed (in part) co-stained with CD31. These endothelial
cells had a high EMAP-II expression before ILP (Fig. 5a, arrow).
In contrast, TNF-R1 expressing cells did not co-stain with the en-
dothelium (Fig. 5a, upper panel). Before ILP, cells with high
TNF-R1 expression located in close proximity to vessels, confirm-
ing our results shown in Figure 4. After ILP, within the disrupted
tumour structure high expressing EMAP-II cells were still present
clustered together. The CD31 positive cells stained positive for
EMAP-II as well. TNF-R1 expression after ILP was again found
in receptor-clusters (Fig. 5a, arrowheads) and the endothelial cells
expressed TNF-R1 at very low levels. Co-staining with CD68
revealed that high EMAP-II expressing cells or regions were asso-
ciated with macrophages. Moreover, this co-staining was in close
proximity to vessel-like structures (Fig. 5b, arrow). The high
TNF-R1 expressing cells in the melanoma tissue before ILP were
macrophages; a strong co-staining was observed for TNF-R1 and
CD68 (Fig. 5b, asterisks). After ILP, the association of EMAP-II
expression and macrophages was still abundant, with similar stain-
ing-patterns. For TNF-R1, association with CD68 positive cells
was less after ILP as compared to before treatment (Fig. 5b, lower
panel, arrowheads point receptor-clusters). Finally, we stained
melanoma tumour biopsies for CD31 and CD68 together (Fig. 5c).
Before ILP, healthy-looking vessels are present and macrophages
were distributed quite equally throughout the tumour tissue. After
ILP vessels appeared disrupted and macrophages were present in
close proximity to these vessel remnants.
EMAP-II and TNF-R1 expression in normal skin and melanoma
From 1 melanoma patient (no. 21) besides a melanoma biopsy
also a biopsy of normal skin was taken before and after TNF-
based ILP. EMAP-II and TNF-R1 expression were determined by
quantitative western blotting. Strikingly, in normal skin, exactly
the opposite occurred compared to the melanoma (Fig. 6a). In the
normal skin the ILP treatment induced an up-regulation of pro-
EMAP and a down-regulation of EMAP-II, while in the melanoma
EMAP-II is upregulated while proEMAP is lower after ILP. Quan-
tification is shown in Figures 6b and 6c. The ratio shows the same
opposite effects for the normal skin versus the melanoma tumour
(Fig. 6d). For TNF-R1 also an opposite effect was found; TNF-R1
expression was high after ILP in the normal skin and before ILP in
the melanoma tumour (Fig. 6a).
Discussion
Here we describe novel data on TNF-R1 and EMAP-II protein
expression in cancer patients treated with a TNF-based ILP. For
melanoma we report an association between EMAP-II and the
response to the TNF-ILP treatment. Our data strongly complement
previous knowledge from preclinical and fundamental studies on
EMAP-II and might have important implications for patients
treated with a TNF-based ILP.
Out of the 350 TNF-based ILPs performed at our institute we
selected patients based on the availability of tumour tissue. For
our study we needed tumour tissue taken directly before and
directly after ILP. Therefore this patient group is unique. The
response rates of the sarcoma and melanoma patients in our
patient group nicely matches the response rates of larger groups
treated by TNF-based ILP.3,22 For sarcomas our study group had
2 CR (14%), which is somewhat lower as compared to larger
cohorts and most likely caused by the relative small group (n 5
14) used in this mechanistic study. The overall response rate is
86% and comparable with other studies.
We employed both immunologic staining and Western blot
analysis, to firstly analyse TNF-R1, proEMAP and EMAP-II
expression levels before and after treatment, in a quantitative man-
ner (Figs. 1 and 2), and secondly to provide insight in localization
of the proteins within the tumour tissues.
Because of the nature of the biopsies, no histological analysis
was possible on sarcoma material and only a fraction of the mela-
noma biopsies can be used. These 3–5 patients were not represent-
ing the whole cohort so findings need to be justified as supportive
and not conclusive observations. Using these melanoma biopsies
we found proEMAP/EMAP-II staining in all cells. In some regions
of the tumour we observed higher expression levels, which might
be due to an up regulation of protein synthesis but, based on co-
staining, we conclude that these regions contained a higher level
of the secreted active EMAP-II cytokine. The high expression pat-
terns have a vessel-like structure (Fig. 4), which we could confirm
when co-stained with CD31 (Fig. 5a) and is in agreement with
other reports.23 For tumour histology analysis we also were re-
stricted to the same melanoma material because we preferred to
have biopsies both directly pre- and post-ILP and only frozen ma-
terial was available, resulting in sections with some gaps. Histo-
logical experiments confirmed the reorganisation of tumour cells.
In HE sections after ILP we observed infiltrate-like cells close to
the vessels and based on specific staining we concluded that these
infiltrate contained macrophages.
Surprisingly, to our knowledge no literature is available on
TNF-R1 distribution within tumour tissue before and after ILP
treatment. Previously, measurements on TNF-R1 were done in se-
rum of patients to determine the concentration of soluble TNF-R1
in response to TNF-based ILP.24,25 Here we show for the first time
TNF-R1 protein distribution in tumour tissue before and after ILP.
We found that TNF-R1 is mainly expressed by cells located
closely to vessels but not by endothelial cells themselves. After
ILP the vascular structure is disrupted and for TNF-R1 we
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observed a cluster-like pattern, a feature reported for other mem-
bers of the death receptor family as well.26 Expression level of
TNF-R1 was however not changed by the perfusion, suggesting
that rather protein redistribution than up- or down-regulation of
TNF-R1 is involved in the anti-tumour effects of TNF.
To attribute expression of EMAP-II and TNF-R1 protein to spe-
cific cells within the heterogeneous tumour tissue we performed
co-staining experiments with endothelial and macrophage/mono-
cyte markers (Fig. 5). Endothelial cells were chosen because of
the known anti-vascular activities of TNF in an ILP and the
FIGURE 4 – (a) Immunofluorescence stainings for EMAP-II (green) and TNF-R1 (red) of melanoma biopsies taken right before (upper panel)
and after (lower panel) TNF-based ILP. Before ILP proEMAP-EMAP-II is present in all cells but some vessel-like regions (arrow) have a higher
expression, likely due to local increased expression of mature EMAP-II. TNF-R1 is mainly expressed in the surrounding of these vessel-like
regions in a scattered manner. Noteworthy is the observation that high EMAP-II expressing cells and TNF-R1 expressing cells de not overlap.
After ILP the tumour structure is extensively damaged. Some high EMAP-II expressing tumour cells clustered to together were observed. TNF-
R1 expression was still present in some tumour cells and appeared more organized in clusters (arrowheads) as compared to before ILP. The ves-
sel-like structures are not visible anymore after ILP. Bar, 50 lm. (b) Histological HE staining of melanoma biopsies taken before and after ILP.
Before ILP the melanoma showed a heterogeneous structure of tumour cells and infiltrate (left panel). After ILP the tumour cells are strongly
redistributed and the tumour-associated macrophages (also called foamy macrophages) tend to cluster, asterisk. Tumour vessels before and after
ILP are shown at the right panel. Bar, 20 lm.
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reported anti-angiogenic properties of EMAP-II1,27 and macro-
phages/monocytes are very well known for their contribution in
tumourgenesis and are one of the major responsive cells to the
chemo attractive activities of EMAP-II.28,29 Co-staining of endo-
thelial cells with EMAP-II implies that high EMAP-II expression
may be involved in the anti-vascular effects of TNF. The absence
of TNF-R1 on tumour endothelium was unexpected. Only after
ILP little positive staining was observed. For endothelial cells
in vitro it is known that they express TNF-R1 and for EMAP-II an
upregulating role has been suggested.16 It is known that TNF-R1
expression is mainly in the Golgi apparatus and only very small
(signalling) fractions are present on the membrane.30 However,
also Golgi-staining was not observed. This might be caused by the
tissue staining procedures, but this also may reflect a major differ-
FIGURE 5 – Immunofluorescence stain-
ings for EMAP-II and TNF-R1 in combina-
tion with endothelial marker (CD31, panel
a) or macrophage/monocyte marker (CD68,
panel b) and co-staining with both markers
(CD31/CD68, panel c) of melanoma biop-
sies taken right before and after TNF-based
ILP. (a) Before ILP the high EMAP-II
expressing regions in part co-localize with
endothelial cells (arrow) while the TNF-R1
expressing cells are surrounding the vessels.
No co-localization of TNF-R1 with endo-
thelial cells was observed. After ILP high
expressing EMAP-II cells were still present
and endothelial cells of the disrupted vessels
stained positive as well. TNF-R1 was ob-
served in clusters (arrowheads) and some
expression was seen in endothelial cells. (b)
Before ILP, high expressing EMAP-II cells/
regions co-stained with macrophages in ves-
sel-like regions (arrow). Most tumour-mac-
rophages expressed high levels of TNF-R1
(asterisks). After ILP co-localization of
EMAP-II and macrophages is obvious while
clustered TNF-R1 expression (arrowheads)
was less associated with macrophages. (c)
Before ILP, healthy-looking vessels are
present and macrophages are equally dis-
tributed throughout the tumour. After ILP
the tumour vasculature has been disrupted
and macrophages were recruited to these en-
dothelial/vessel remnants.
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ence between endothelial cells in culture and those of tumour ves-
sels. The fact that there is no co-staining of endothelial cells and
TNF-R1 shows that the underlying mechanism responsible for the
TNF response is much more multifaceted than the simple binding
of TNF to TNF-R1 on endothelial cells resulting in endothelial
cell apoptosis. We speculate that during TNF-based ILP a whole
set of cytokines, growth factors and cells are involved, thereby
changing the tumour pathophysiology, like cellular organization
and vascular flow, which opens windows for TNF and melphalan
to exert their anti-tumour activities.
Experiments with co-staining for macrophages confirm this hy-
pothesis and pinpoint macrophages and EMAP-II as important
players during TNF-based ILP. The tumour-associated macro-
phages are located in regions of high EMAP-II expression and are
attracted by the chemo attractive properties of EMAP-II to vascu-
lar structures before ILP (Fig. 5b). Also after ILP there is still a
strong co-localization of EMAP-II and macrophages, which
implies that EMAP-II is still after ILP directing macrophages to
specific sites. These sites are regions of vascular remnants as
revealed by co-staining of endothelial cells and macrophages
(Fig. 5c). While before ILP the vessels are intact and the macro-
phages are spread throughout the tumour, after ILP the macro-
phages are recruited to sites of vascular destruction. Our data show
that EMAP-II is an important regulator of this process. For TNF-R1
we observed co-staining with macrophages only before ILP. This
might indicate a role for TNF-R1 in activating the tumour-associ-
ated macrophages during their suggested role in tumour response.
These observations, the fact that TNF targets endothelial cells
within solid tumours and that all these observations were made
directly after ILP imply that TNF attributes mainly to these phe-
nomena. Unfortunately, no control tissue was available of (mela-
noma) patients treated with Melphalan alone for verification,
because all patients get the optimal TNF 1 Melphalan treatment.
Additionally, the anti-vascular and cytokine dependent (macro-
phage) effects will be much lower in the melphalan alone group
making adequate evaluation complicated.
The opposing effect of ILP treatment on proEMAP-EMAP-II in
the normal skin as compared to the melanoma tumour (Fig. 6) is a
remarkable finding but only done in 1 patient. TNF selectively dis-
rupts tumour vasculature; maybe the effects on EMAP-II and macro-
phages recruitment may be tumour specific. The high EMAP-II
expression in the normal skin can be explained by the high level of
cell turnover and replacement, which occurs in healthy skin tissue.31
Besides the observed EMAP-II effect on macrophages during
ILP treatment, an important observation of our study is the rela-
tionship between EMAP-II expression and CR of melanoma
patients after TNF-based ILP. Particularly, the correlation was
found for the active cytokine EMAP-II, and not for proEMAP, ra-
tio or TNF-R1 (Table II). This correlation between EMAP-II and
clinical response strongly suggests an important function of
EMAP-II both in mechanism and in clinical outcome. For sarco-
mas no correlation was found. The relatively small group of
patients we studied (n 5 14) may be responsible for this but more-
over, sarcomas are very heterogeneous tumours and our group
consists of many different subtypes. In addition, sarcoma tumours
had a lower EMAP-II expression as compared to melanomas and
depending on tumour type EMAP-II is expressed at different lev-
els and by different mechanisms.12 A role of EMAP-II in sarcoma
regression is not ruled out but for sarcomas additional factors
might play crucial roles. We speculate that a certain threshold of
EMAP-II needs to be reached to establish its reported effects and
this likely is strongly dependent on tumour type and tumour
micro-environmental composition like matrix composition, infil-
tration and vascular density. Our results justify further experimen-
tal analysis of the function of EMAP-II in anti-tumour activities of
TNF. This will lead to more insight in this process and possibil-
ities to intervene and manipulate the EMAP-II expression or activ-
ity improving response rates in the clinical setting. In conclusion,
we propose that analysis of EMAP-II expression in tumour biop-
sies of melanoma patients should be implemented in the ILP-pro-
cedure so this correlation could be defined in a randomised trial
within a larger patient group.
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